Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

shankar besta

  • Home
  • Author: shankar besta

Experts believe gene therapies will disrupt Gaucher disease drug market, says GlobalData

Following the conclusion of International Gaucher Disease Awareness Month, key opinion leaders (KOLs) interviewed by GlobalData believe pipeline gene therapies will significantly impact the Gaucher disease landscape. Gene therapy has the curative potential to provide patients with a healthy GBA1 copy, disrupting the Gaucher drug market. However, much groundwork remains to be covered, says GlobalData, […]
Read more

Masimo’s medical watch regulatory approval to bolster remote patient monitoring space, says GlobalData

In the ever-evolving landscape of healthcare technology, medical smartwatches are emerging as transformative devices that seamlessly integrate health monitoring into our daily lives. One notable development in this space is the recent FDA clearance for Masimo‘s medical watch for both prescription and over-the-counter (OTC) use. The clearance will provide a significant boost to the remote […]
Read more

FDA’s recall of stolen laryngoscopes highlights need for increased vigilance on online healthcare marketplace, says GlobalData

In a recent development, the Food and Drug Administration (FDA) issued a medical device recall, targeting stolen Medtronic laryngoscopes that were illicitly sold on the popular online platform, Facebook Marketplace. This unprecedented move highlights the pressing need for increased vigilance in the realm of online commerce, particularly within the healthcare sector, says GlobalData, a leading […]
Read more

Positive post hoc analysis of SCORED trial to bolster Inpefa use for heart failure, says GlobalData

At this year’s American Heart Association Scientific Session, positive results were presented from Lexicon Pharmaceuticals’ SCORED analysis of Inpefa (sotagliflozin), providing insight into the drug’s ability to significantly reduce the risk of heart failure (HF) in as little as three months. The post hoc analysis could be of high clinical value to cardiologists looking to […]
Read more

Microsoft’s GenAI capabilities continue to impress, says GlobalData

Occupying center stage at Ignite 2023 was Microsoft Copilot, the company’s virtual assistant and umbrella brand for its AI capabilities. At the event, Microsoft introduced hybrid work capabilities infused with GenAI that touch multiple Microsoft 365 apps, offer diverse functionality, and are well positioned, according to research conducted by GlobalData, a leading data and analytics […]
Read more

New generative AI capabilities are a win for RingCentral, says GlobalData

RingCX contact center and RingCentral Events are the new generative AI capabilities added by RingCentral to increase productivity, making contact center agents and event planners (respectively) even more valuable to their organizations.  The new capabilities place RingCentral in an enviable spot, according to research conducted by GlobalData, a leading data and analytics company. Gregg Willsky, […]
Read more

Oncology KRAS-targeting therapy market to exceed $4 billion by 2029, forecasts GlobalData

Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are common in solid tumors, including lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The introduction of KRAS inhibitors has become a significant advancement in the quickly developing area of oncology, providing hope in the battle against difficult solid tumors. The global market for KRAS-targeting drugs in […]
Read more

Arrowhead Pharmaceuticals’ plozarsiran and zodasiran hold potential to treat dyslipidemia, says GlobalData

At the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia, Arrowhead Pharmaceuticals unveiled the Phase II clinical data for plozasiran (ARO-APOC3) and zodasiran (ARO-ANG3). The Phase II SHASTA-2 study showed that plozasiran decreased APOC3 to -79%, triglycerides (TGs) to -74%, remnant cholesterol to -65% and increased high-density lipoprotein (HDL)-cholesterol (HDL-C) to 68% at 24 […]
Read more

FDA’s Fast Track designation for Altimmune’s pemvidutide reinforces use of GLP-1RAs in NASH, says GlobalData

In October 2023, the FDA granted Fast Track designation for Altimmune’s incretin mimetic, pemvidutide, in non-alcoholic steatohepatitis (NASH). Pemvidutide is a glucagon-like peptide 1 (GLP-1) glucagon receptor (GCGR) dual agonist peptide (GLP-1R/GCGR) currently in Phase IIb development for NASH (IMPACT trial) and for obesity (MOMENTUM trial). The Fast Track designation is supported by the data […]
Read more

Verve’s gene-editing therapy trial to lower cholesterol levels opens doors for use in cardiovascular disease, says GlobalData

The first human clinical trial of a novel gene-editing technique known as base editing has shown promising results in maintaining healthy levels of cholesterol. In the trial by Verve Therapeutics, physicians injected patients with a Clustered Regularly Interspace Short Palindromic Repeats (CRISPR)-based gene editing therapy called VERVE-101, which inactivated the liver gene PCSK9 that typically […]
Read more
1 … 94 95 96 97 98 … 136